A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial

Objective Inflammation at the entheses is a distinguishing feature of spondyloarthritis (SpA). Enthesitis at the heel is the most common location and is often chronic, refractory to standard treatment and may have socioeconomic consequences. The objective of this study was to investigate the efficacy of etanercept in refractory heel enthesitis related to SpA. Methods The present work was a 12-week, randomised, double-blind, placebo-controlled study compared etanercept with placebo in patients with SpA according to Amor's criteria, and heel enthesitis proven by MRI. The primary efficacy end point was the normalised net incremental area under the curve (AUC) between randomisation and week 12 for the patient's global assessment (PGA) of disease activity. Secondary end points included change from baseline in PGA, heel pain, the Western Ontario and McMaster Universities Osteoarthritis index (WOMAC) function subscale and improvement in enthesitis as measured by MRI. Results A total of 24 patients were randomised. Mean normalised net incremental AUC for PGA of disease activity over 12 weeks was significantly greater in the etanercept versus placebo group: −28.5 versus −11.1, respectively (p=0.029). Significant improvements were also reported in the etanercept versus placebo group for PGA, −37.6 versus −11.6 (p=0.007); heel pain, −36.7 versus −13.1 (p=0.022); and WOMAC function, −23.2 versus −7.8 (p=0.024). No significant changes were observed in the MRI findings between groups. No unexpected adverse events or changes in laboratory values or vital signs. Conclusions This trial is the first randomised placebo-controlled study of an anti-tumour necrosis factor (TNF) agent in refractory heel enthesitis in patients with SpA. It demonstrates that etanercept has a statistically significant and clinically relevant benefit in such patients. ClinicalTrials.gov identifier NCT00420303.

[1]  E. Märker-Hermann,et al.  The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. , 2009, Arthritis and rheumatism.

[2]  E. Naredo,et al.  Validity of enthesis ultrasound assessment in spondyloarthropathy , 2008, Annals of the rheumatic diseases.

[3]  P. Rahman,et al.  Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study. , 2007, Arthritis and rheumatism.

[4]  M. Dougados,et al.  Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis , 2007, Annals of the rheumatic diseases.

[5]  D. Gladman,et al.  International spondyloarthritis interobserver reliability exercise--the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. , 2007, The Journal of rheumatology.

[6]  A. Boonen,et al.  The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice , 2007, Annals of the rheumatic diseases.

[7]  Stanley B. Cohen,et al.  Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. , 2006, The Journal of rheumatology.

[8]  J. Braun,et al.  Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab. , 2005, Rheumatology.

[9]  Philippe Ravaud,et al.  Minimal clinically important difference, low disease activity state, and patient acceptable symptom state: methodological issues. , 2005, The Journal of rheumatology.

[10]  M. Dougados,et al.  Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks , 2005, Annals of the rheumatic diseases.

[11]  John C. Davis,et al.  Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor α receptor fusion protein etanercept , 2005 .

[12]  J. Braun,et al.  Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept , 2005, Arthritis and rheumatism.

[13]  A. Kavanaugh,et al.  Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial , 2005, Annals of the rheumatic diseases.

[14]  J. Sharp,et al.  Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. , 2004, Arthritis and rheumatism.

[15]  J. Braun,et al.  Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept. , 2004, The Journal of rheumatology.

[16]  M. Dougados,et al.  Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. , 2003, Arthritis and rheumatism.

[17]  J. Braun,et al.  Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. , 2003, Arthritis and rheumatism.

[18]  M. Dougados,et al.  Assessment of enthesitis in ankylosing spondylitis , 2003, Annals of the rheumatic diseases.

[19]  John C. Davis,et al.  Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. , 2002, The New England journal of medicine.

[20]  H. Zeidler,et al.  Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial , 2002, The Lancet.

[21]  M. Dougados,et al.  Refractory inflammatory heel pain in spondylarthropathy: a significant response to infliximab documented by ultrasound. , 2002, Arthritis and rheumatism.

[22]  P. Emery,et al.  Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. , 2001, Arthritis and rheumatism.

[23]  G. Panayi.  Therapy of Systemic Rheumatic Disorders , 1998 .

[24]  A. Calin,et al.  A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. , 1994, The Journal of rheumatology.

[25]  M. Dougados,et al.  The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. , 1991, Arthritis and rheumatism.

[26]  M. Dougados,et al.  [Criteria of the classification of spondylarthropathies]. , 1990, Revue du rhumatisme et des maladies osteo-articulaires.

[27]  C. Goldsmith,et al.  Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. , 1988, The Journal of rheumatology.

[28]  J. Simpson,et al.  Studies with an enthesis index as a method of clinical assessment in ankylosing spondylitis. , 1987, Annals of the rheumatic diseases.

[29]  H. Yazici,et al.  Enthesopathy index in ankylosing spondylitis , 2022 .